Organized by top academic experts in lung cancer and thoracic malignancies, this is THE thoracic CME Conference that you should attend: Lung cancer specialists from a wide range of disciplines will share information on the latest developments in basic, clinical and translational research.

Access the Webcast    See the Abstract Book online    Print certificate of attendance

Interview with Dr Ken O'Byrne on the prognostic role of KRAS mutation in non-small cell lung cancer Dr O'Byrne says this study is a positive step forward in identifying a definite target in a real way	Interview with Dr Tony Mok on the clinical implications of the biomarker analysis of the TORCH trial Dr Mok highlights the strong value of EGFR mutation status when selecting the most effective treatment sequence in advanced NSCLC
Abstract 164O KRAS mutational status impact progression free survival of patients treated with platinum based chemotherapy in NSCLC M.C. Garassino1, S. Veronese1, M. Marabese1, E. Rulli2, G. Farina2, F. Longo3, M.A. Fabbri4, S. Piva2, O. Martelli5, A. Scanni2 1Milano/IT, 2Milan/IT, 3Roma/IT, 4Viterbo/IT, 5Rome/IT	Abstract 163O Biomarkers of TORCH Trial on First-line Erlotinib Followed by Second-line Chemotherapy in Advanced Non-Small Cell Lung Cancer Patients M.S. Tsao1, C. Gallo2, M. Saieg1, G.D.C. Santos1, V. Gebbia3, F. Perrone2, C. Butts4, F. Ciardiello2, R. Feld5, C. Gridelli6 1Toronto/CA, 2Napoli/IT, 3Palermo/IT, 4Edmonton, AB/CA, 5Toronto, ON/CA, 6Avellino/IT

Interview with Dr Carbone on symptom evaluation from a study using the new agent dacomitinib Dr Carbone stresses the importance of symptom control and quality of life when treating NSCLC patients

Abstract 166O Evaluation of symptom impact of dacomitinib (PF-00299804) vs erlotinib in patients with advanced NSCLC after chemotherapy failure: results from a phase 2 randomized clinical trial J. O'Connell1, A. Bottomley2, S.S. Ramalingam3, M. Boyer4, K. Park5, F. Blackhall6, R. Mundayat7, A. Campbell1 1Groton, CT/US, 2Brussels/BE, 3Atlanta, GA/US, 4Camperdown, NSW/AU, 5Seoul/KR, 6Manchester/UK, 7New York, NY/US

If you missed the Press Conference and would like to listen to a recording of it, please follow the link below:

Listen to the ELCC Press Conference